Items Tagged ‘precison medicine’

June 15th, 2017

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used as initial treatment for advanced […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, PD-1, pembrolizumab, precison medicine, Yervoy


May 15th, 2017

Avelumab Immunotherapy Approved for Bladder Cancer

By

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Discuss this article with other patients and caregivers- CancerConnect. About Urothelial Cancer Bladder […]

View full entry

Tags: Bavencio Avelumab, Bladder Cancer, News, precison medicine